Plasmapheresis in the treatment of antiphospholipid syndrome
Published on: 2019-01-04
In recent years there is a growing interest to the whole group of diseases, having common pathogenetic developmental mechanisms. We are talking about the antiphospholipid syndrome, which has been well studied in obstetric practice, because it is accompanied by disorders of fetal development and habitual miscarriages. Nevertheless, in general somatic practice it plays one of the leading roles in vascular pathology, both in the venous circulation, leading to deep vein thrombosis and thromboembolism of the pulmonary vessels and in the arterial circulation that results in occlusive complications, including myocardial infarction and ischemic strokes. Symptomatic drug therapy and anticoagulants are commonly used, ignoring the primary cause of the vascular wall lesion induced by antibodies. Plasmapheresis should be considered to be the most pathogenically justified therapy, aimed to remove antiphospholipid autoantibodies, which are the primary factors of such conditions.